The European Union's clinical trials database lists a phase 3 trial of petrelintide, a once weekly amylin drug, in adults with overweight or obesity and type 2 diabetes as authorised, with recruitment pending. The sponsor is Roche, which develops the drug with Zealand Pharma. The primary endpoint is the percent change in body weight at week 64.
The record plans 679 participants in total: 195 at 21 sites in Czechia, Germany, Hungary and Poland, and 484 outside the EU and the wider European Economic Area. The page gives two decision dates, 10 November 2026 in its overview and 8 November in its timeline, without explaining the difference, so the authorisation can only be dated to early November.
What the phase 2 trials showed
ZUPREME-1 randomised 493 people with overweight or obesity and no diabetes to petrelintide or placebo. At week 42, mean weight fell by up to 10.7% on petrelintide against 1.7% on placebo using the efficacy estimand, and by up to 10.2% against 1.4% using the treatment policy estimand. Zealand says gastrointestinal side effects were mostly mild and occurred at rates similar to placebo, with no vomiting and no stopping because of gastrointestinal effects at the most effective dose. The company announced at the end of September that the results had been published in The Lancet Diabetes & Endocrinology.
ZUPREME-2, a 28 week phase 2b trial, enrolled 220 adults in the United States who had type 2 diabetes and took metformin, with or without an SGLT2 inhibitor. Across three doses, mean weight loss was 7.4% to 9.2% against 2.0% on placebo, using the efficacy estimand. HbA1c, a measure of blood sugar control, fell by up to 0.65% with petrelintide and rose by 0.23% with placebo. Stopping because of side effects was 1.9% with petrelintide and 1.7% with placebo. These are company reported topline results that have not been peer reviewed.
The phase 3 programme
Zealand and Roche have started a phase 3a programme of three trials, ZUPREME-3, ZUPREME-4 and ZUPREME-5, which plans about 7,000 participants in total. They cover people without type 2 diabetes, people with it, and people with established cardiovascular disease, and the first participants have begun treatment.
What is still unknown
Analysts at William Blair, quoted by Fierce Biotech, said the weight loss across the two phase 2 trials, and the HbA1c effect in ZUPREME-2, disappointed. Lilly's amylin drug eloralintide lost up to about 20% at 48 weeks in 263 people without diabetes in a phase 2 trial, but the trials differ in length and design and no trial has compared the two drugs. ZUPREME-2 lasted only 28 weeks, so long term weight loss and tolerability are unknown.
The EU record does not say which programme trial it belongs to. Fierce Biotech reported ZUPREME-4 as recruiting 600 people, against 679 in the EU record. Petrelintide is not approved anywhere.